anti-EGFR monoclonal antibody

DRUG6 trials

Sponsors

Dragonboat Biopharmaceutical Company Limited, Sinocelltech Ltd., Shi Yuankai, Fudan University, Second Affiliated Hospital of Soochow University

Conditions

Advanced Refractory Solid TumorsColorectal CancerHead and Neck CancerHead and Neck Squamous Cell CarcinomaHealthy VolunteersOropharyngeal Carcinoma

Phase 1

A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC

Dragonboat Biopharmaceutical Company LimitedColorectal Cancer

Start: 2018-07-01End: 2019-12-01Updated: 2019-10-31

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux

Dragonboat Biopharmaceutical Company LimitedHealthy Volunteers

Start: 2019-02-27End: 2019-12-30Target: 84Updated: 2019-03-20

Phase 2

Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma

Sinocelltech Ltd.Head and Neck Cancer

Start: 2018-11-28End: 2020-05-28Target: 40Updated: 2020-03-23

SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma

Shi YuankaiHead and Neck Squamous Cell Carcinoma

Start: 2018-12-30End: 2020-05-28Target: 30Updated: 2018-11-16

Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

Fudan UniversityOropharyngeal Carcinoma

Start: 2016-01-01End: 2023-12-01Target: 52Updated: 2022-04-04

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Not yet recruitingNCT07327411

Second Affiliated Hospital of Soochow UniversityAdvanced Refractory Solid Tumors

Start: 2025-12-27End: 2027-11-10Target: 40Updated: 2026-01-08